INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 51 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $93,000 | -30.1% | 173,842 | 0.0% | 0.00% | – |
| Q4 2017 | $133,000 | -49.8% | 173,842 | -3.3% | 0.00% | – |
| Q3 2017 | $265,000 | -45.4% | 179,802 | 0.0% | 0.00% | – |
| Q2 2017 | $485,000 | -49.3% | 179,802 | -23.8% | 0.00% | – |
| Q1 2017 | $956,000 | -0.4% | 236,078 | +3.3% | 0.00% | – |
| Q4 2016 | $960,000 | -35.2% | 228,590 | +4.9% | 0.00% | -100.0% |
| Q3 2016 | $1,481,000 | +27.2% | 217,852 | +8.1% | 0.00% | 0.0% |
| Q2 2016 | $1,164,000 | -16.4% | 201,554 | +1.0% | 0.00% | 0.0% |
| Q1 2016 | $1,393,000 | +16.2% | 199,623 | +19.8% | 0.00% | 0.0% |
| Q4 2015 | $1,199,000 | -16.2% | 166,647 | +0.4% | 0.00% | 0.0% |
| Q3 2015 | $1,430,000 | – | 165,989 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IMS Capital Management | 246,966 | $1,778,000 | 2.19% |
| WELCH & FORBES LLC | 902,286 | $6,496,000 | 0.21% |
| Alambic Investment Management, L.P. | 25,100 | $181,000 | 0.11% |
| EMERSON INVESTMENT MANAGEMENT, LLC | 74,175 | $534,000 | 0.10% |
| Hayek Kallen Investment Management | 10,965 | $79,000 | 0.06% |
| Yellowstone Partners, LLC | 10,045 | $72,000 | 0.03% |
| Ausdal Financial Partners, Inc. | 7,750 | $56,000 | 0.03% |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 29,647 | $213,000 | 0.03% |
| GROUP ONE TRADING, L.P. | 61,856 | $445,000 | 0.01% |
| Cambridge Investment Research Advisors, Inc. | 10,500 | $76,000 | 0.00% |